Credit Suisse Research Report, page-10

Hi Ice, don’t put too much faith in anything I say and as always DYOR but I personally do not believe that a deal relies on any more clinical results.

That said each result does show the uniqueness of what we have. We (AVR) already know how the valve is performing in 4 patients and as mentioned below the current results from all three studies are proving very positive data. So the company already knows how the studies are going.

Our tissue is already in over 20k patients so we don’t need a rat study to tell us it’s better than the Comp. That has already been proven. The valve has past proof of concept (in SAVR), and the Pigs are going well so far with the valve implanted in 3 pigs on a catheter (TAVR) with excellent EOA’s achieved. Some of these studies are also primarily to assist us in securing FDA breakthrough status.

Below is from the company:

“Anteris continues to engage with potential strategic partners. The data and insights from clinical and pre-clinical trials are critical to these important discussions.”

”Our research and development programs are going from strength to strength with two key studies commencing this quarter. Also, three more patients were successfully implanted with our 3D single-piece aortic valve in our first-in-human SAVR trial. The results from all three studies are providing very positive data and useful insights into our tissue science and valve design.”

The aim is to definitely achieve capital through non dilutive means. Personally I think they can do it and the Symposium was the clincher. The medical world now knows that we are getting results that no one has ever seen before.

To me even with a CR this is worth so much more than an EV of approx 15 million. Add to this the deal with LeMatre, tissue supply for 4C medical (TMVR) with a potential market twice the size of TAVR, the potential of CABG, SAVR and other studies starting this quarter I think we are incredible value here.

That’s just me and AVR is not for everyone. However, the quality of our TAVR Dr’s and the fact they really want DurAVR to succeed coupled with the genuine results we are given gives me confidence to buy.

DYOR and certainly not advice. AVR is a risky stock with amazing potential.